Varun Capoor: How Therapeutic Apheresis and Transfusion Medicine Can Complement Clinical Management in SCD
Varun Capoor, Senior Consultant and Incharge Transfusion Medicine Specialist at Paras Health, shared a post on LinkedIn:
“Red Cell Exchange in Sickle Cell Disease: The Role of Transfusion Medicine in Perioperative Care
A recent case highlighted for me how Therapeutic Apheresis and Transfusion Medicine can complement clinical management in Sickle Cell Disease (SCD)—particularly when a patient is being prepared for major surgery.
A 21-year-old male with SCD, Hb 9.5 g/dL and Hct 27.2%, was planned for elective hip hemiarthroplasty.
With Hb already around 9.5 g/dL, simple transfusion could increase red-cell mass and potentially blood viscosity.
After multidisciplinary discussion, automated red cell exchange (RCE) was chosen to reduce the circulating HbS burden while maintaining the patient’s red-cell volume.
The RCE
Automated RCE was performed using a COM.TEC cell separator.
- Blood volume processed: 5,205 mL
- TBV: 4,985 mL
- Pre/post Hct: 27%
- RBC replacement volume: 1,850 mL
HPLC: Before – After
- HbS: 77% – 18.2%
- HbA: 2.4% – 76.7%
- HbF: 11.3% – 2.2%
The important observation was the substantial reduction in HbS without increasing the Hct, which illustrates one of the key principles of RCE: changing the composition of circulating RBCs rather than simply adding more RBC mass.
Where does Transfusion Medicine fit in?
The apheresis procedure is only one component of the process.
For patients with SCD, transfusion planning involves:
- Review of previous transfusions and historical antibodies
- Antibody screening and identification
- Extended RBC phenotype/genotype where appropriate
- Appropriate Rh and Kell antigen matching
- Selection of compatible, leukoreduced RBC components
- Monitoring for acute and delayed haemolytic transfusion reactions
- Appropriate pre- and post-RCE laboratory assessment
In this patient, the RBC selection was based on his ABO/Rh status, extended Rh phenotype and Kell status, with a negative antibody screen.
The bigger lesson
Preoperative transfusion in SCD should be individualized according to the patient’s Hb, HbS%, clinical phenotype, surgical risk and transfusion history.
RCE can be particularly useful when a significant reduction in HbS is desired but simply increasing haemoglobin through top-up transfusion is undesirable.
In this case:
- HbS 77% – 18.2%
- Hct 27% – 27%
A good example of how Apheresis plus Transfusion Medicine plus Haematology plus Anaesthesia plus Surgery can work together to optimize a patient before major surgery.
Better transfusion decisions.
Better apheresis practice.
Better patient care.”
Stay updated with Hemostasis Today.
-
Nov 10, 2026, 16:28Can the VWF to ADAMTS-13 Ratio Predict Mortality in Sepsis-Induced Coagulopathy? – RPTH Journal
-
Nov 10, 2026, 16:28Ruth Willems: PhD Defence at Maastricht University on Thrombosis and Bleeding in HPB Disease
-
Nov 10, 2026, 16:09Edward Lee Carter: Factor XIa Inhibition Enters Clinical Practice
-
Nov 10, 2026, 16:08Edward C.C. Wong: Deriving Ferritin Cutoffs for Iron Deficiency Using RBC Parameters
-
Nov 10, 2026, 16:07Milad Abdalla: Decoding Hemoglobin Electrophoresis – A Practical Diagnostic Reference
-
Nov 10, 2026, 15:13Wolfgang Miesbach: Nonviral Gene Therapy for Haemophilia A Using Lipid Nanoparticles
-
Nov 10, 2026, 15:06Dahra Teles: First Speaking Experience at HEMO 2026 on First-Line Multiple Myeloma Treatment
-
Nov 10, 2026, 14:55Yazan Abou-Ismail: First FDA-Approved Factor XIa Inhibitor for Stroke Prevention
-
Nov 10, 2026, 14:49Ifeanyichukwu Ifechidere: The Role of Coagulation in Anaesthesia and Surgery